Instructions for Credit — There is no fee for this activity. To receive credit for this CE activity, participants must enroll in this course, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.5 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or email@example.com.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers at the intermediate and advanced levels involved in the care of patients with acute myeloid leukemia (AML).
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the various types and subtypes of AML|
|•||Identify tests used to diagnose disease and monitor treatment of AML|
|•||Explain the overarching goals of treatment for the types of AML|
|•||Explain approved and emerging treatment options for AML, including stem cell transplantation, and the role of clinical trials|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for AML|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioner Credit Designation
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19013542. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.5 CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.5 CE clinical contact hours for this activity.
For questions, grievances, or assistance with special needs (physical,. dietary, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Pinkal Desai, MD, MPH, is on the Advisory Board for Argenx and Cellerant Therapeutics, Inc. She is also a Consultant for Cellerant Therapeutics, Inc.
Peter Campbell, PharmD, BCOP, is on the Advisory Board for INSYS Therapeutics, Inc.
Ayelet Nelson, LMSW, NP, has nothing to disclose.
Darci L. Zblewski, APRN, C-NP, OCN®, Content Expert Reviewer, has nothing to disclose.
Disclaimer — The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: 1.5 hours|
|Date of initial release: April 1, 2019|
|Valid for CE credit through: April 1, 2020|
|Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medicine
Assistant Attending Physician
New York-Presbyterian Hospital
New York, NY
Pinkal Desai MD, MPH, is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York-Presbyterian Hospital in New York, New York.
After obtaining her MBBS at Byramjee Jeejeebhoy Medical College in India in 2005, Dr. Desai obtained an MPH at the University of Alabama at Birmingham School of Public Health in Birmingham, Alabama. Following her residency at Wayne State University, Detroit Medical Center in Detroit, Michigan, she underwent fellowship training in hematology-medical oncology at Providence Hospital Medical Center, serving as Chief Fellow from 2012 to 2013. Dr. Desai was recruited to the Leukemia Program at New York-Presbyterian Hospital to develop a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN). She will be developing clinical and translational research protocols and projects in the areas of leukemia, MDS, and MPN.
Dr. Desai’s work has been published in Cancer Epidemiology, Biomarkers & Prevention and the International Journal of Molecular Epidemiology and Genetics. She is the lead author and co-author on numerous WHI (Women’s Health Initiative paper proposals and has presented abstracts at national meetings. She is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) and has served on the ASCO University Committee.
|Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager, Hematology/Oncology
Columbia University Irving Medical Center
New York, NY
Peter Campbell, PharmD, BCOP, is a Clinical Pharmacy Manager at Columbia University Irving Medical Center in New York, New York. Dr. Campbell is a Board-Certified Oncology Pharmacist, and his area of specialized clinical practice is in acute and chronic leukemias, with a primary practice site of the inpatient setting. Dr. Campbell is also the Program Director for the PGY2 oncology pharmacy residency at New York-Presbyterian Hospital.
Dr. Campbell graduated from St. John’s University College of Pharmacy and Allied Health Professions in Queens, New York. He then completed a pharmacy practice residency followed by an oncology pharmacy specialty residency at New York-Presbyterian Hospital.
|Ayelet Nelson, RN, LMSW, ANP-BC
Leukemia Outpatient Nurse Practitioner
Weill Cornell Medicine
New York, NY
Ayelet Nelson, RN, LMSW, ANP-BC, is a Leukemia Outpatient Nurse Practitioner at Weill Cornell Medicine in New York, New York, where she monitors and treats patients with hematologic malignancies utilizing both standard treatments as well as innovative treatments administered as part of clinical trials. Ms. Nelson earned her Masters of Social Work at the New York University Silver School of Social Work in New York, New York, and continued her education by completing the Adult Nurse Practitioner Master’s Program at the Boston College Connell School of Nursing in Chestnut Hill, Massachusetts. She is passionate about working with each patient as an individual to address his or her unique needs throughout the journey of a cancer diagnosis while providing compassionate care. She has also helped to initiate a support group for young adult patients with leukemia.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
AML Specific Resources – www.LLS.org/AML
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Additional support resources: www.LLS.org/support
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists